EMA Lapsed: Docetaxel Mylan (docetaxel) — Mylan S.A.S.

View source ↗

Summary

EMA status shows Docetaxel Mylan has lapsed; related indications include head and neck neoplasms, non-small cell lung carcinoma, adenocarcinoma, prostatic neopl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Breast Neoplasms
• Carcinoma of the Lung
• Head and Neck Neoplasms
• Prostatic Neoplasms

Drugs mentioned

• Docetaxel Mylan (docetaxel)

Snippet

Status: Lapsed. Therapeutic area: Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Prostatic Neoplasms;Breast Neoplasms. MAH: Mylan S.A.S.. Decision date: 01/02/2015